ClinicalTrials.gg
CompletedNCT01373151Updated Dec 6, 2021Results posted

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

A Phase 2 interventional study of BMS-945429 Placebo and BMS-945429 in Rheumatoid Arthritis, sponsored by CSL Behring. Completed at 100 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-06.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 153 studies in Arthritis, Rheumatoid with a site in Japan — 9 open to participants now, 12 under way, 2 of them phase 3. Arthritis, Rheumatoid · Japan.

Enrollment
41st of 132
418 · median 265
Started
2011
with 9 others
Phase 2
36 of 153
2 open now
Registered
56th of 153
by date

Among the 153 studies in Arthritis, Rheumatoid with a site in Japan, this one is the 41st largest by enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2011, is one of 36 in phase 2, and was the 56th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 153 studies in Arthritis, Rheumatoid with a site in Japan are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Arthritis, Rheumatoid with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inadequate response to Methotrexate
  • Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization
  • American College of Rheumatology (ACR) global function status class 1-3
  • Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist
  • High sensitivity C-reactive protein (hsCRP) ≥ 0.8 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Previously received or currently receiving concomitant biologic therapy
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
418 participants (actual)

Study arms

  • Placebo comparator
    Arm 1

    BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo

    Drug: BMS-945429 Placebo · Biological: BMS-945429 · Drug: Methotrexate · Drug: Adalimumab Placebo

  • Experimental
    Arm 2

    BMS-945429 + Methotrexate + Adalimumab Placebo

    Biological: BMS-945429 · Drug: Methotrexate · Drug: Adalimumab Placebo

  • Experimental
    Arm 3

    BMS-945429 + Methotrexate + Adalimumab Placebo

    Biological: BMS-945429 · Drug: Methotrexate · Drug: Adalimumab Placebo

  • Experimental
    Arm 4

    BMS-945429 + Methotrexate + Adalimumab Placebo

    Biological: BMS-945429 · Drug: Methotrexate · Drug: Adalimumab Placebo

  • Experimental
    Arm 5

    BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo

    Biological: BMS-945429 · Drug: Methotrexate Placebo · Drug: Methotrexate · Drug: Adalimumab Placebo

  • Experimental
    Arm 6

    BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo

    Biological: BMS-945429 · Drug: Methotrexate Placebo · Drug: Methotrexate · Drug: Adalimumab Placebo

  • Active comparator
    Arm 7

    Adalimumab + Methotrexate

    Drug: Methotrexate · Drug: Adalimumab

Interventions

  • DrugBMS-945429 Placebo

    Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only

  • BiologicalBMS-945429

    Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only

  • BiologicalBMS-945429

    Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks

  • BiologicalBMS-945429

    Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48

  • BiologicalBMS-945429

    Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks

  • Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only

  • Tablets, Oral, 15 mg, Weekly, 48 weeks

  • DrugMethotrexate Placebo

    Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only

  • Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only

  • DrugAdalimumab Placebo

    Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks

  • Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks

06

What researchers measure

Primary outcomes

  1. Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Time frame: At 12 Weeks

Secondary outcomes

  1. Percent of Participants With ACR 20 Response

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Time frame: At 24 weeks

  2. Percent of Participants Achieving ACR 50 Response Rate

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Time frame: At weeks 12 and 24

  3. Percent of Participants Achieving ACR 70 Response Rate

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Time frame: At weeks 12 and 24

  4. Mean Change From Baseline in Disease Activity as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)

    DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.

    Time frame: Baseline, weeks 12 and 24

  5. Percent of Participants With Remission by DAS28-CRP

    DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.

    Time frame: At weeks 12 and 24

  6. Mean Change From Baseline in Clinical Disease Activity Index (CDAI)

    CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity

    Time frame: Baseline, weeks 12 and 24

  7. Percent of Participants With Remission by CDAI

    CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity

    Time frame: At weeks 12 and 24

  8. Mean Change From Baseline in Simplified Disease Activity Index (SDAI)

    SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity

    Time frame: Baseline, weeks 12 and 24

  9. Percent of Participants With Remission by SDAI

    SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity

    Time frame: At weeks 12 and 24

  10. Percent of Participants With Remission Rate by Boolean Definition

    Boolean-based definition: At any time point, a patient must satisfy all of the following: TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)

    Time frame: At weeks 12 and 24

  11. Mean Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index

    Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.

    Time frame: Baseline, weeks 12 and 24

  12. Mean Change From Baseline in Short Form 36 (SF-36) as Measured by Physical and Mental Components

    The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.

    Time frame: Baseline, weeks 12 and 24

  13. Mean Change From Baseline in Fatigue Severity (VAS) Score

    A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.

    Time frame: Baseline, weeks 12 and 24

  14. Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Scores

    The WPAI yeilds four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivty loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment WPAI outcomes are expressed as impairment percentages with each subscale score ranging from 0-100. The subscale scores are added and averaged to produce a total WPAI score between 0-100. Higher scores indicate greater impairment and less productivity.

    Time frame: Baseline, weeks 12 and 24

  15. Mean Change From Baseline in Radiographic (MRI) Progression of Synovitis, Osteitis (Bone Marrow Edema), Bone Erosion and Cartilage Loss (Joint-space Narrowing)

    Time frame: Baseline and week 12

  16. Mean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score

    The Sharp-van der Heijde total score ranges from 0-528. Scores for erosion range from 0 to 5 in the hands and 0 to 10 in the feet and reflect erosion size, with 0 defined as no erosion and 3 defined as a large erosion passing the midline of the joint. If there is \> 1 erosion per joint, scores can be combined to give a maximum score of 5 per joint in the hands and 10 per joint in the feet (a maximum of 5 at each side of the joint). Joint space narrowing scores vary from 0 to 4 in both the hands and feet, with 0 being normal and 4 being the absence of joint space with evident ankylosis or subluxation. Gross osteolysis and pencil-in-cup change are scored separately and, if present, are assigned the maximum score for erosion and joint space narrowing for the same affected joint. Higher scores indicate increased joint damage.

    Time frame: Baseline and week 24

07

Results

Posted Dec 6, 2021

Participant flow

Period 1
Participant flow — Period 1
MilestonePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
Started61596060596059
Completed56595659545659
Not completed5041540
Withdrew: Lack of efficacy3000100
Withdrew: Adverse event0010430
Withdrew: Withdrawal by subject2031010
Period 2
Participant flow — Period 2
MilestonePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
Started56585659545559
Completed47575254525554
Not completed9145205
Withdrew: Lack of efficacy9001203
Withdrew: Adverse event0033001
Withdrew: Subject request to discontinue0100000
Withdrew: Withdrawal by subject0001000
Withdrew: Other0010001

Outcome measures

PrimaryPercent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate

The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

Time frame:
At 12 Weeks
Reported as:
Number · percentage of participants
Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate
percentage of participantsPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate39.376.355.073.361.060.076.3
SecondaryPercent of Participants With ACR 20 Response

The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

Time frame:
At 24 weeks
Reported as:
Number · percentage of participants
Percent of Participants With ACR 20 Response
percentage of participantsPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
Percent of Participants With ACR 20 Response37.781.458.365.057.666.766.1
SecondaryPercent of Participants Achieving ACR 50 Response Rate

The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

Time frame:
At weeks 12 and 24
Reported as:
Number · percentage of participants
Percent of Participants Achieving ACR 50 Response Rate
percentage of participantsPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
12 weeks21.349.226.743.328.826.730.5
24 weeks16.447.536.746.733.943.347.5
SecondaryPercent of Participants Achieving ACR 70 Response Rate

The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

Time frame:
At weeks 12 and 24
Reported as:
Number · percentage of participants
Percent of Participants Achieving ACR 70 Response Rate
percentage of participantsPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
12 weeks8.218.613.326.711.913.311.9
24 weeks6.627.116.740.025.430.018.6
SecondaryMean Change From Baseline in Disease Activity as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)

DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.

Time frame:
Baseline, weeks 12 and 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Disease Activity as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
score on a scalePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
12 weeks-1.15 ± 0.1652-2.65 ± 0.1610-2.29 ± 0.1603-2.68 ± 0.1597-2.34 ± 0.1665-2.52 ± 0.1610-2.04 ± 0.1647
24 weeks-1.69 ± 0.1825-3.01 ± 0.1684-2.60 ± 0.1719-3.06 ± 0.1713-2.55 ± 0.1769-2.95 ± 0.1706-2.52 ± 0.1769
SecondaryPercent of Participants With Remission by DAS28-CRP

DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.

Time frame:
At weeks 12 and 24
Reported as:
Number · percentage of participants
Percent of Participants With Remission by DAS28-CRP
percentage of participantsPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 121.635.621.735.025.426.720.3
week 2411.549.225.040.035.641.723.7
SecondaryMean Change From Baseline in Clinical Disease Activity Index (CDAI)

CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity

Time frame:
Baseline, weeks 12 and 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Clinical Disease Activity Index (CDAI)
score on a scalePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 12-14.5 ± 1.727-22.7 ± 1.686-17.7 ± 1.687-23.1 ± 1.701-19.8 ± 1.738-21.0 ± 1.697-22.4 ± 1.702
week 24-20.3 ± 1.703-26.1 ± 1.587-22.0 ± 1.613-26.9 ± 1.622-21.7 ± 1.643-25.6 ± 1.606-26.2 ± 1.631
SecondaryPercent of Participants With Remission by CDAI

CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity

Time frame:
At weeks 12 and 24
Reported as:
Number · percentage of participants
Percent of Participants With Remission by CDAI
percentage of participantsPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 123.311.98.38.33.43.38.5
week 241.615.36.721.76.820.08.5
SecondaryMean Change From Baseline in Simplified Disease Activity Index (SDAI)

SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity

Time frame:
Baseline, weeks 12 and 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Simplified Disease Activity Index (SDAI)
score on a scalePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 12-14.5 ± 1.794-24.9 ± 1.749-20.4 ± 1.745-25.3 ± 1.734-22.2 ± 1.811-23.3 ± 1.747-23.2 ± 1.785
week 24-20.6 ± 1.812-28.4 ± 1.670-24.5 ± 1.704-29.1 ± 1.698-23.5 ± 1.755-27.6 ± 1.691-27.6 ± 1.752
SecondaryPercent of Participants With Remission by SDAI

SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity

Time frame:
At weeks 12 and 24
Reported as:
Number · percentage of participants
Percent of Participants With Remission by SDAI
percentage of participantsPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 121.611.98.38.36.85.010.2
week 244.918.66.720.6.823.38.5
SecondaryPercent of Participants With Remission Rate by Boolean Definition

Boolean-based definition: At any time point, a patient must satisfy all of the following: TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)

Time frame:
At weeks 12 and 24
Reported as:
Number · percentage of participants
Percent of Participants With Remission Rate by Boolean Definition
percentage of participantsPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 123.38.56.710.1.75.05.1
week 241.610.25.013.35.118.310.2
SecondaryMean Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index

Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.

Time frame:
Baseline, weeks 12 and 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index
score on a scalePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 12-0.44 ± 0.0827-0.66 ± 0.0801-0.47 ± 0.0807-0.70 ± 0.0811-0.51 ± 0.0834-0.60 ± 0.0807-0.60 ± 0.0819
week 24-0.62 ± 0.0861-0.68 ± 0.0806-0.64 ± 0.0823-0.79 ± 0.0823-0.60 ± 0.0840-0.71 ± 0.0811-0.66 ± 0.0833
SecondaryMean Change From Baseline in Short Form 36 (SF-36) as Measured by Physical and Mental Components

The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.

Time frame:
Baseline, weeks 12 and 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Short Form 36 (SF-36) as Measured by Physical and Mental Components
score on a scalePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
Mental component (week 12)5.3 ± 1.2745.9 ± 1.2404.5 ± 1.2517.3 ± 1.2444.0 ± 1.2835.7 ± 1.2306.4 ± 1.250
Mental component (week 24)6.0 ± 1.3276.4 ± 1.2086.6 ± 1.2477.5 ± 1.2475.3 ± 1.2718.0 ± 1.2197.1 ± 1.246
Physical component (week 12)4.0 ± 1.0307.5 ± 0.9997.3 ± 1.0109.5 ± 1.0026.8 ± 1.0287.3 ± 0.9948.4 ± 1.006
Physical component (week 24)6.2 ± 1.1498.6 ± 1.0459.4 ± 1.08010.9 ± 1.0767.7 ± 1.0948.2 ± 1.0578.2 ± 1.077
SecondaryMean Change From Baseline in Fatigue Severity (VAS) Score

A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.

Time frame:
Baseline, weeks 12 and 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fatigue Severity (VAS) Score
score on a scalePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 12-14.3 ± 3.146-20.8 ± 3.060-19.4 ± 3.077-27.4 ± 3.077-21.7 ± 3.180-18.6 ± 3.056-26.3 ± 3.080
week 24-12.9 ± 3.306-23.9 ± 3.052-22.3 ± 3.131-31.3 ± 3.103-17.7 ± 3.184-23.4 ± 3.056-27.0 ± 3.134
SecondaryMean Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Scores

The WPAI yeilds four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivty loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment WPAI outcomes are expressed as impairment percentages with each subscale score ranging from 0-100. The subscale scores are added and averaged to produce a total WPAI score between 0-100. Higher scores indicate greater impairment and less productivity.

Time frame:
Baseline, weeks 12 and 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
score on a scalePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
week 12-9.6 ± 3.273-2.2 ± 3.443-8.7 ± 3.673-12.0 ± 3.081-13.7 ± 3.285-10.0 ± 3.575-11.7 ± 6.281
week 24-10.7 ± 4.033-1.8 ± 3.893-17.1 ± 4.200-12.1 ± 3.448-5.9 ± 3.788-12.6 ± 3.938-4.7 ± 6.379
SecondaryMean Change From Baseline in Radiographic (MRI) Progression of Synovitis, Osteitis (Bone Marrow Edema), Bone Erosion and Cartilage Loss (Joint-space Narrowing)
Time frame:
Baseline and week 12
Reported as:
Mean · cubic millimeters
Mean Change From Baseline in Radiographic (MRI) Progression of Synovitis, Osteitis (Bone Marrow Edema), Bone Erosion and Cartilage Loss (Joint-space Narrowing)
cubic millimetersPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
Erosion1.3 ± 0.3520.4 ± 0.3411.1 ± 0.3560.3 ± 0.3341.0 ± 0.369-0.2 ± 0.341-0.5 ± 0.348
Edema0.2 ± 1.009-6.4 ± 0.993-2.6 ± 1.015-4.7 ± 0.998-4.6 ± 1.036-5.1 ± 0.993-3.1 ± 1.008
Synovitis-0.5 ± 0.436-2.5 ± 0.427-1.4 ± 0.440-2.2 ± 0.426-2.9 ± 0.447-2.5 ± 0.427-2.9 ± 0.435
Narrowing0.1 ± 0.133-0.1 ± 0.1300.2 ± 0.135-0.1 ± 0.1260.1 ± 0.1390.0 ± 0.129-0.2 ± 0.132
SecondaryMean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score

The Sharp-van der Heijde total score ranges from 0-528. Scores for erosion range from 0 to 5 in the hands and 0 to 10 in the feet and reflect erosion size, with 0 defined as no erosion and 3 defined as a large erosion passing the midline of the joint. If there is \> 1 erosion per joint, scores can be combined to give a maximum score of 5 per joint in the hands and 10 per joint in the feet (a maximum of 5 at each side of the joint). Joint space narrowing scores vary from 0 to 4 in both the hands and feet, with 0 being normal and 4 being the absence of joint space with evident ankylosis or subluxation. Gross osteolysis and pencil-in-cup change are scored separately and, if present, are assigned the maximum score for erosion and joint space narrowing for the same affected joint. Higher scores indicate increased joint damage.

Time frame:
Baseline and week 24
Reported as:
Mean · score on a scale
Mean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score
score on a scalePlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
Mean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score1.8 ± 0.3530.3 ± 0.3200.0 ± 0.3270.1 ± 0.3240.1 ± 0.3300.1 ± 0.3360.1 ± 0.333

Adverse events

Collected over Up to 48 weeks per participant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo+MTX0/61 (0%)2/61 (3.3%)24/61 (39.3%)
Clazakizumab(25)+MTX0/59 (0%)5/59 (8.5%)43/59 (72.9%)
Clazakizumab(100)0/60 (0%)5/60 (8.3%)43/60 (71.7%)
Clazakizumab(100)+MTX0/60 (0%)5/60 (8.3%)51/60 (85%)
Clazakizumab(200)0/59 (0%)8/59 (13.6%)43/59 (72.9%)
Clazakizumab(200)+MTX0/60 (0%)5/60 (8.3%)50/60 (83.3%)
ADA+MTX0/59 (0%)3/59 (5.1%)35/59 (59.3%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
OverdoseInjury, poisoning and procedural complications0/611/590/600/603/590/600/59
CellulitisInfections and infestations0/612/590/600/600/590/600/59
AppendicitisInfections and infestations0/610/590/602/600/590/600/59
PneumoniaInfections and infestations0/610/590/601/600/590/601/59
Pulmonary tuberculosisInfections and infestations0/610/590/601/601/590/600/59
Bursitis infectiveInfections and infestations0/610/590/600/601/590/600/59
Herpes zosterInfections and infestations0/610/590/600/600/590/601/59
Urinary tract infectionInfections and infestations0/610/590/600/601/590/600/59
Foot fractureInjury, poisoning and procedural complications0/611/590/600/600/590/600/59
Acute coronary syndromeCardiac disorders0/611/590/600/600/590/600/59
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlacebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTX
Alanine aminotransferase increasedInvestigations2/6111/592/6013/601/5918/603/59
Ejection site erythemaGeneral disorders0/612/598/6015/6010/599/602/59
Injection site reactionGeneral disorders0/618/599/6011/6014/599/601/59
Aspartate aminotransferase increasedInvestigations0/618/590/6014/600/5912/602/59
HypercholesterolaemiaMetabolism and nutrition disorders2/617/597/605/605/599/602/59
Injection site rashGeneral disorders0/611/598/608/602/598/600/59
Upper respiraory tract infectionInfections and infestations7/615/591/603/607/591/600/59
DyslipidaemiaMetabolism and nutrition disorders1/617/594/602/602/594/601/59
Injection site dermatitisGeneral disorders0/614/593/604/604/597/600/59
NasopharyngitisInfections and infestations4/612/593/604/603/597/602/59

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTXTotal
<=18 years00000000
Between 18 and 65 years54564752515551366
>=65 years7313885852
Age, Continuous
Age, Continuous(years)Placebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTXTotal
Mean51.4 ± 11.0347.4 ± 10.9755.0 ± 12.2149.9 ± 13.9550.0 ± 12.5346.4 ± 11.9152.8 ± 11.4150.4 ± 12.26
Sex: Female, Male
Sex: Female, Male(Participants)Placebo+MTXClazakizumab(25)+MTXClazakizumab(100)Clazakizumab(100)+MTXClazakizumab(200)Clazakizumab(200)+MTXADA+MTXTotal
Female46465253494948343
Male15138710111175
08

Study locations

100 sites
  • Sun Valley Arthritis Center, Ltd.
    Peoria, Arizona 85381, United States
  • San Diego Arthritis Medical Clinic
    San Diego, California 92108, United States
  • New England Research Associates, Llc
    Trumbull, Connecticut 06611, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Rockford Orthopedic Associates, Llc.
    Rockford, Illinois 61107, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Arthritis Associates Of Mississippi
    Jackson, Mississippi 39202, United States
  • Physician Research Collaboration, Llc
    Lincoln, Nebraska 68516, United States
  • Box Arthritis And Rheumatology Of The Carolinas, Pllc
    Charlotte, North Carolina 28210, United States
  • Health Research Of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • East Penn Rheumatology Associates, P.C.
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98104, United States
  • Local Institution
    Capital Federal, Buenos Aires 1015, Argentina
  • Local Institution
    Capital Federal, Buenos Aires 1425, Argentina
  • Local Institution
    Capital Federal, Buenos Aires 1428, Argentina
  • Local Institution
    Capital Federal, Buenos Aires 1431, Argentina
  • Local Institution
    Rosario, Santa FE 2000, Argentina
  • Local Institution
    San Miguel De Tucuman, Tucuman 4000, Argentina
  • Local Institution
    Cordoba, 5000, Argentina
  • Local Institution
    San Juan, 5400, Argentina
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Hasselt, 3500, Belgium
  • Local Institution
    Goiania, Goias 74110, Brazil
  • Local Institution
    Juiz De Fora, Minas Gerais 36010, Brazil
  • Local Institution
    Curitiba, Parana 80060, Brazil
  • Local Institution
    Curitiba, Parana 80440, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 91610, Brazil
  • Local Institution
    Sao Paulo, 04032, Brazil
  • Local Institution
    Sao Paulo, 04266, Brazil
  • Local Institution
    Montreal, Quebec H2L 1S6, Canada
  • Centre De Recherche Musculo-Squelettique
    Trois-rivieres, Quebec G8Z 1Y2, Canada
  • Local Institution
    Quebec, G1W 4R4, Canada
  • Local Institution
    Praha 2, 128 50, Czechia
  • Local Institution
    Praha 4, 140 59, Czechia
  • Local Institution
    Bordeaux Cedex, 33076, France
  • Local Institution
    Chambray Les Tours, 37170, France
  • Local Institution
    Strasbourg Cedex, 67098, France
  • Local Institution
    Berlin, 14059, Germany
  • Local Institution
    Koeln, 50931, Germany
  • Local Institution
    Leipzig, 04103, Germany
  • Local Institution
    Wuerzburg, 97080, Germany
  • Local Institution
    Budapest, 1027, Hungary
  • Local Institution
    Debrecen, 4012, Hungary
  • Local Institution
    Gyula, 5700, Hungary
  • Local Institution
    Veszprem, 8200, Hungary
  • Local Institution
    Napoli, 80131, Italy
  • Local Institution
    Padova, 35128, Italy
  • Local Institution
    Reggio Emilia, 42100, Italy
  • Local Institution
    Chiba-shi, Chiba 2608712, Japan
  • Local Institution
    Kitakyushu-shi, Fukuoka 8078555, Japan
  • Local Institution
    Higashi-hiroshima-shi, Hiroshima 7390002, Japan
  • Local Institution
    Kato-shi, Hyogo 6731462, Japan
  • Local Institution
    Miyazaki-shi, Miyazaki 8800122, Japan
  • Local Institution
    Nagano-shi, Nagano 3808582, Japan
  • Local Institution
    Nagasaki-shi, Nagasaki 8528501, Japan
  • Local Institution
    Sasebo-shi, Nagasaki 8571195, Japan
  • Local Institution
    Tomigusuku-shi, Okinawa 9010243, Japan
  • Local Institution
    Osaka-shi, Osaka 5458586, Japan
  • Local Institution
    Shizuoka-shi, Shizuoka 4208623, Japan
  • Local Institution
    Bunkyo-ku, Tokyo 1138519, Japan
  • Local Institution
    Shinjuku-Ku, Tokyo 1608582, Japan
  • Local Institution
    Toshima-ku, Tokyo 1708476, Japan
  • Local Institution
    Daegu, 705-718, Korea, Republic of
  • Local Institution
    Seoul, 133-792, Korea, Republic of
  • Local Institution
    Seoul, 137-701, Korea, Republic of
  • Local Institution
    Mexico City, Distrito Federal 11850, Mexico
  • Local Institution
    Guadalajara, Jalisco 42650, Mexico
  • Local Institution
    Guadalajara, Jalisco 45040, Mexico
  • Local Institution
    Morelia, Michioacan 58270, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64020, Mexico
  • Local Institution
    Culiacan, Sinaloa 80230, Mexico
  • Local Institution
    San Luis Potosi, 78213, Mexico
  • Local Institution
    Amsterdam, 1056 AB, Netherlands
  • Local Institution
    Katowice, 40-748, Poland
  • Local Institution
    Krakow, 31-531, Poland
  • Local Institution
    Poznan, 60773, Poland
  • Local Institution
    Warszawa, 01-868, Poland
  • Local Institution
    Warszawa, 02-118, Poland
  • Local Institution
    Ekaterinburg, 620102, Russian Federation
  • Local Institution
    Kazan, 420064, Russian Federation
  • Local Institution
    Moscow, 115522, Russian Federation
  • Local Institution
    Novosibirsk, 630005, Russian Federation
  • Local Institution
    St. Petersburg, 191014, Russian Federation
  • Local Institution
    Yaroslavl, 150003, Russian Federation
  • Local Institution
    Pretoria, Gauteng 0083, South Africa
  • Local Institution
    Pretoria, Gauteng 0132, South Africa
  • Local Institution
    Durban, KWA ZULU Natal 4001, South Africa
  • Local Institution
    Panorama, Western CAPE 7500, South Africa
  • Local Institution
    Pinelands, Cape Town, Western Cape 7405, South Africa
  • Local Institution
    Tygerberg, Western CAPE 7505, South Africa
  • Local Institution
    A Coruna, 15006, Spain
  • Local Institution
    Madrid, 28040, Spain
  • Local Institution
    Santander, 39008, Spain
  • Local Institution
    Santiago De Compostela, 15706, Spain
  • Local Institution
    Sevilla, 41071, Spain
  • Local Institution
    Changhua, 500, Taiwan
  • Local Institution
    Kaohsiung, 833, Taiwan
  • Local Institution
    Taichung, 404, Taiwan
  • Local Institution
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015 Oct;67(10):2591-600. doi: 10.1002/art.39249. PubMed 26138593 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Sep 2012 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2021, 9 years 3 months after primary completion. A results delay was requested in Jul 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2011
First posted
Jun 14, 2011
Start
Jun 2011
Primary completionActual
Sep 2012
CompletionActual
Jun 2015
Results delay requested
Jul 24, 2015
Results first posted
Dec 6, 2021
Last update
Dec 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01373151
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jun 14, 2011
Start date
Jun 2011
Primary completion
Sep 2012
Completion
Jun 2015
Results posted
Dec 6, 2021
Last update
Dec 6, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clazakizumab

Start the discussion